Cerebrovascular Effects of the Use of Alpha-stat or pH-stat Management of Cardiopulmonary Bypass

NCT ID: NCT03816280

Last Updated: 2019-05-16

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-02-01
• Study Completion Date: 2020-07-31

Brief Summary

Type 2 diabetes mellitus (T2DM) poses a significant burden on the patients and the health care system. The increasing number of surgery performed in elderly population results in an increased number of perioperative T2DM-related adverse effects. T2DM has a prevalence of 30-40% in a population undergoing cardiovascular surgery. Cardiac surgery, especially cardiopulmonary bypass (CPB) is also known to deteriorate cerebral oxygenation.

Furthermore, acid-base balance of patients undergoing CPB can be managed using two main regimes: alpha-stat and pH-stat. The use of pH-stat acid-base management involves maintaining the patient's temperature-corrected pH at a constant level (7.40) and maintaining normocapnia (pCO2 of 40 mmHg). Alpha-stat acid-base management on the other hand is performed by maintaining the ionization state of histidine by keeping the pH stable when a standardized temperature of 37C is used. Therefore, while a constant pH (7.40) and normocapnia (pCO2 of 40 mmHg) are targeted when measured at 37C, the hypothermia applied during CPB will result in a lower pCO2 and in a relative respiratory alkalosis. Previous studies investigating alpha-stat and pH-stat managements demonstrated increased jugular venous oxygen concentrations when pH-stat management was applied.

Therefore, our study is aimed at characterizing the effects of an alpha-stat or pH-stat acid-base management regime on the cerebral oxygenation, parameters of regional cerebral oxygen supply and demand during and following CPB in diabetic patients. These parameters include regional cerebral tissue oxygen saturation (rSO2), central venous oxygen saturation ScvO2) and the physiological saturation gap between ScvO2 and rSO2 (gSO2).

Detailed Description

One hour before the surgery, patients are premedicated with lorazepam (per os, 2.5 mg). Induction of anaesthesia is achieved by iv midazolam (30 μg/kg), sufentanyl (0.4-0.5 μg/kg), and propofol (0.3-0.5 mg/kg), and iv propofol (50 mg/kg/min) is administered to maintain anaesthesia. Intravenous boluses of rocuronium (0.6 mg/kg for induction and 0.2 mg/kg every 30 minutes for maintenance) is administered iv to ensure neuromuscular blockade. A cuffed tracheal tube (internal diameter of 7, 8, or 9 mm) is used for tracheal intubation, and patients are mechanically ventilated (Dräger Zeus, Lübeck, Germany) in volume-controlled mode with decelerating flow. A tidal volume of 7 ml/kg and a positive end-expiratory pressure of 4 cmH2O are applied, and the ventilation frequency is adjusted to 12-14 breaths/min to maintain end-tidal CO2 partial pressure of 36 38 mmHg. Mechanical ventilation is performed with a fraction of inspired oxygen of 0.5 before CPB, and it is increased to 0.8 after CPB. As a standard part of the cardiac anaesthesia procedure, oesophageal and rectal temperature probes are introduced, and a central venous line is inserted into the right jugular vein. The left radial artery is also cannulated to monitor systolic, diastolic and mean arterial (MAP) blood pressures and arterial blood gas samples.

The membrane oxygenator is primed with 1,500 ml lactated Ringer's solution prior to CPB. Intravenous heparin (300 U/kg) is injected into the patient, to achieve an activated clotting time of 400 s during CPB procedures. During CPB, mild hypothermia is allowed, the mechanical ventilation is stopped, and the ventilator is disconnected without applying positive airway pressure. Before restoring ventilation, the lungs are inflated 3-5 times to a peak airway pressure of 30 cmH2O to facilitate lung recruitment.

After securing arterial and peripheral venous lines and placement of NIRS and entropy sensors, data collection is initiated immediately before anesthesia induction in all groups of patients. Since catheterization of the jugular vein is scheduled after anesthesia induction, ScvO2 and gSO2 data are not available at the first protocol stage. After induction and before surgical incision, all measurements are repeated. The whole data set is registered at the beginning of CPB after clamping the aorta and 5 min before the end of CPB. The final stage of the protocol is allocated to the end of the operation after sternal closure. All invasive (i.e. arterial and venous blood gas) and non-invasive (i.e. NIRS) data are registered simultaneously at each protocol stage.

Sample sizes are estimated to enable the detection of a 10% difference in the primary outcome parameter gSO2 that we considered clinically significant. Accordingly, sample-size estimation based on an ANOVA test with 4 groups of patients (diabetic and control patients undergoing CPB with alpha-stat or pH-stat acid-base regime) indicated that 100 patients were required in each group to detect a significant difference between the protocol groups.

Two-way repeated measures ANOVA with the inclusion of an interaction term is used for all measured variables with the protocol stage as within-subject factor (protocol stages) and group allocation as between-subject factor to establish the effects of T2DM and the acid-base management regime on the parameters of cerebral oxygenation. At half-way of the data collection, an interim analyses will be performed and the further data collection will be proceeded based on the results of this analysis.

Conditions

Diabetes Mellitus; Cardiac Surgical Procedures

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Group T2DM-alpha

Patients with diabetes mellitus undergoing CPB with alpha-stat acid-base management

Elective cardiopulmonary bypass (CPB)

Intervention Type: PROCEDURE

All groups undergo elective cardiopulmonary bypass (CPB)

Alpha-stat acid-base management

Intervention Type: PROCEDURE

Acid-base status during CPB will be maintained using the alpha-stat regime

Group T2DM-pH

Patients with diabetes mellitus undergoing CPB with pH-stat acid-base management

Elective cardiopulmonary bypass (CPB)

Intervention Type: PROCEDURE

All groups undergo elective cardiopulmonary bypass (CPB)

pH-stat acid-base management

Intervention Type: PROCEDURE

Acid-base status during CPB will be maintained using the pH-stat regime

Group Ctrl-alpha

Control patients undergoing CPB with alpha-stat acid-base management

Elective cardiopulmonary bypass (CPB)

Intervention Type: PROCEDURE

All groups undergo elective cardiopulmonary bypass (CPB)

Alpha-stat acid-base management

Intervention Type: PROCEDURE

Acid-base status during CPB will be maintained using the alpha-stat regime

Group Ctrl-pH

Control patients undergoing CPB with pH-stat acid-base management

Elective cardiopulmonary bypass (CPB)

Intervention Type: PROCEDURE

All groups undergo elective cardiopulmonary bypass (CPB)

pH-stat acid-base management

Intervention Type: PROCEDURE

Acid-base status during CPB will be maintained using the pH-stat regime

Interventions

Elective cardiopulmonary bypass (CPB)

All groups undergo elective cardiopulmonary bypass (CPB)

Intervention Type: PROCEDURE

Alpha-stat acid-base management

Acid-base status during CPB will be maintained using the alpha-stat regime

Intervention Type: PROCEDURE

pH-stat acid-base management

Acid-base status during CPB will be maintained using the pH-stat regime

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Patients undergoing cardiac surgery with or without diabetes mellitus
• age between 18-80 years

Exclusion Criteria

• patients older than 80 years of age
• poor ejection fraction (<40%)
• unilateral internal carotid stenosis (>75%)
• medical history of smoking
• medical history of chronic obstructive pulmonary disease
• medical history of stroke

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GINOP

UNKNOWN

Sponsor Role: collaborator

Hungarian Basic Research Council

OTHER

Sponsor Role: collaborator

Szeged University

OTHER

Sponsor Role: lead

Responsible Party

Barna Babik

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Cardiology Centre Cardiac Surgical Unit and Second Department of Internal Medicine, University of Szeged

Szeged, Csongrád megye, Hungary

Site Status: RECRUITING

Countries

Hungary

Central Contacts

Barna Babik, MD, PhD

Role: CONTACT

babikbarna@gmail.com

+36 20 3876480 ext. +36 62 542349

Facility Contacts

Barna Babik, MD, PhD

Role: primary

babikbarna@gmail.com

+36 62 542349

Other Identifiers

WHO2788-b

Identifier Type: -

Identifier Source: org_study_id